Klin Monbl Augenheilkd 2016; 6(03): 227-241
DOI: 10.1055/s-0042-109874
Georg Thieme Verlag KG Stuttgart · New York

Lymphomerkrankungen des Auges

Ocular Lymphomas
Vinodh Kakkassery
Klinik für Augenheilkunde, Universitätsklinikum Knappschaftskrankenhaus Bochum – Ruhr-Universität Bochum
Marc Ilan Wunderlich
Klinik für Augenheilkunde, Universitätsklinikum Knappschaftskrankenhaus Bochum – Ruhr-Universität Bochum
› Author Affiliations
Further Information

Publication History

Publication Date:
05 August 2016 (online)

Lymphome sind maligne Entartungen des lymphatischen Systems. Sie können sowohl systemisch auftreten als auch isoliert das Auge betreffen und sind als potenziell lebensbedrohliche Erkrankung anzusehen. Ziel des Artikels ist es, eine Übersicht zum komplexen Krankheitsbild der okularen Lymphome zu geben und ein evidenzbasiertes Schema zur diagnostischen und therapeutischen Vorgehensweise sowie zur engmaschigen Nachkontrolle mit psychoonkologischer Betreuung zu präsentieren.

  • Literatur

  • 1 Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Genf: World Health Organization; 2008
  • 2 Klinke R, Bauer C, Silbernagl S. Lehrbuch der Physiologie. Stuttgart: Thieme; 2003
  • 3 Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol 2015; 16: e555-e567
  • 4 Armitage JO, Coiffier B, Dalla-Favera R. Non-Hodgkin Lymphomas. Alphen aan den Rijn: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009
  • 5 Chaudhary RK, Bhatt VR, Vose JM. Management of extranodal natural killer/t-cell lymphoma, nasal type. Clin Lymphoma Myeloma Leuk 2015; 15: 245-252
  • 6 Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkinʼs Disease Staging Classification. Cancer Res 1971; 31: 1860-1861
  • 7 Rath S, Connors JM, Dolman PJ et al. Comparison of American Joint Committee on Cancer TNM-based staging system (7th ed.) and Ann Arbor classification for predicting outcome in ocular adnexal lymphoma. Orbit 2014; 33: 23-28
  • 8 Coupland SE, White VA, Rootman J et al. A TNM-based clinical staging system of ocular adnexal lymphomas. Arch Pathol Lab Med 2009; 133: 1262-1267
  • 9 Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood 2009; 114: 501-510
  • 10 Freemann E. [Nursing research]. Osterr Krankenpflegez 1974; 27: 293-295
  • 11 Moslehi R, Devesa SS, Schairer C et al. Rapidly increasing incidence of ocular non-hodgkin lymphoma. J Natl Cancer Inst 2006; 98: 936-939
  • 12 Andrew NH, McNab AA, Selva D. Review of 268 lacrimal gland biopsies in an Australian cohort. Clin Experiment Ophthalmol 2015; 43: 5-11
  • 13 Andreoli MT, Aakalu V, Setabutr P. Epidemiological trends in malignant lacrimal gland tumors. Otolaryngol Head Neck Surg 2015; 152: 279-283
  • 14 Kirkegaard MM, Coupland SE, Prause JU et al. Malignant lymphoma of the conjunctiva. Surv Ophthalmol 2015; 60: 444-458
  • 15 Ferreri AJ, Guidoboni M, Ponzoni M et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96: 586-594
  • 16 Ferreri AJ, Viale E, Guidoboni M et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol 2006; 17: 769-772
  • 17 Theander E, Henriksson G, Ljungberg O et al. Lymphoma and other malignancies in primary Sjogrenʼs syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803
  • 18 Aronow ME, Portell CA, Sweetenham JW et al. Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology 2014; 121: 334-341
  • 19 Coupland SE, Foss HD, Hidayat AA et al. Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases. J Pathol 2002; 197: 333-340
  • 20 Mashayekhi A, Shields CL, Shields JA. Iris involvement by lymphoma: a review of 13 cases. Clin Experiment Ophthalmol 2013; 41: 19-26
  • 21 Doycheva D, Zierhut M, Süsskind D et al. Diagnostik und Therapie der choroidalen Lymphome. Ophthalmologe 2015; 112: 217-222
  • 22 Chan CC, Rubenstein JL, Coupland SE et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011; 16: 1589-1599
  • 23 Sagoo MS, Mehta H, Swampillai AJ et al. Primary intraocular lymphoma. Surv Ophthalmol 2014; 59: 503-516
  • 24 Mulay K, Narula R, Honavar SG. Primary vitreoretinal lymphoma. Indian J Ophthalmol 2015; 63: 180-186
  • 25 Matsuo T, Ichimura K, Kubonishi S. Mantle cell lymphoma diagnosed by conjunctival salmon-pink lesion biopsy. J Clin Exp Hematop 2014; 54: 143-147
  • 26 Kakkassery V, Stubiger N, Adamietz IA et al. [Lymphoma of the ocular adnexa]. Ophthalmologe 2015; 112: 210-216
  • 27 Stubiger N, Kakkassery V, Gundlach E et al. [Diagnostics and treatment of primary vitreoretinal lymphoma]. Ophthalmologe 2015; 112: 223-230
  • 28 Loriaut P, Charlotte F, Bodaghi B et al. Choroidal and adnexal extranodal marginal zone B-cell lymphoma: presentation, imaging findings, and therapeutic management in a series of nine cases. Eye (Lond) 2013; 27: 828-835
  • 29 Polito E, Galieni P, Leccisotti A. Clinical and radiological presentation of 95 orbital lymphoid tumors. Graefes Arch Clin Exp Ophthalmol 1996; 234: 504-509
  • 30 Newman JS, Francis IR, Kaminski MS et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-116
  • 31 Hoffman PM, McKelvie P, Hall AJ et al. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (Lond) 2003; 17: 513-521
  • 32 Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 2004; 242: 901-913
  • 33 Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med 2013; 15: 93-100
  • 34 Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina 2011; 31: 435-440
  • 35 Bonzheim I, Giese S, Deuter C et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood 2015; 126: 76-79
  • 36 Tuo J, Shen D, Yang HH et al. Distinct microRNA-155 expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis. Am J Ophthalmol 2014; 157: 728-734
  • 37 White LM, Schweitzer ME, Khalili K et al. MR imaging of primary lymphoma of bone: variability of T2-weighted signal intensity. Am J Roentgenol 1998; 170: 1243-1247
  • 38 Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012; 380: 848-857
  • 39 Sallak A, Besson FL, Pomoni A et al. Conjunctival MALT lymphoma: utility of FDG PET/CT for diagnosis, staging, and evaluation of treatment response. Clin Nucl Med 2014; 39: 295-297
  • 40 Stafford SL, Kozelsky TF, Garrity JA et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001; 59: 139-144
  • 41 Regueiro CA, Valcarcel FJ, Romero J et al. Treatment of conjunctival lymphomas by beta-ray brachytherapy using a strontium-90-yttrium-90 applicator. Clin Oncol (R Coll Radiol) 2002; 14: 459-463
  • 42 Heinz C, Merz H, Nieschalk M et al. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland. Br J Ophthalmol 2007; 91: 1563-1564
  • 43 Tuncer S, Tanyildiz B, Basaran M et al. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. Curr Eye Res 2015; 40: 780-785
  • 44 Ferreri AJ, Govi S, Colucci A et al. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology 2011; 118: 24-28
  • 45 Savino G, Battendieri R, Gari M et al. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. J Cancer Res Clin Oncol 2013; 139: 1251-1255
  • 46 Ferreri AJ, Ponzoni M, Martinelli G et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 2005; 90: 1578-1579
  • 47 Ferreri AJ, Govi S, Pasini E et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012; 30: 2988-2994
  • 48 Jusufbegovic D, Kim V, Char DH. Primary uveal lymphoma with epibulbar extension masquerading as an intraocular inflammation. Can J Ophthalmol 2015; 50: e24-e26
  • 49 Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina 2009; 29: 129-132
  • 50 Grimm SA, McCannel CA, Omuro AM et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group report. Neurology 2008; 71: 1355-1360
  • 51 Bilsing B, Anger B, Meyer F. [Medical Rehabilitation in Gastrointestinal Oncology]. Zentralbl Chir 2015; 140: 382-389
  • 52 Zeissig SR, Singer S, Koch L et al. [Utilisation of psycho-oncological services in hospitals and outpatient counselling centres by survivors of breast, colon and prostate cancer]. Psychother Psychosom Med Psychol 2015; 65: 177-182
  • 53 Singer S, Danker H, Briest S et al. Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (STEPPED CARE): study protocol for a cluster randomized controlled trial. Trials 2014; 15: 482
  • 54 Baraniskin A, Kuhnhenn J, Schlegel U et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011; 117: 3140-3146
  • 55 Baraniskin A, Kuhnhenn J, Schlegel U et al. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neurooncol 2012; 109: 239-244
  • 56 Riemens A, Bromberg J, Touitou V et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol 2015; 133: 191-197
  • 57 Ben Abdelwahed R, Donnou S, Ouakrim H et al. Preclinical study of ublituximab, a glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013; 54: 3657-3665